tiprankstipranks
Trending News
More News >

Sinopharm Announces Board Changes with New Director Appointment

Story Highlights
  • Sinopharm’s independent director, Mr. Chen Fangruo, resigns after completing his term.
  • Mr. Chen Weiru is proposed as a new independent director, pending shareholder approval.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Sinopharm Group Co ( (HK:1099) ) has provided an update.

Sinopharm Group Co. Ltd. announced the resignation of Mr. Chen Fangruo as an independent non-executive director due to the completion of his term. The company expressed gratitude for his contributions to its development and governance. Concurrently, the board proposed the appointment of Mr. Chen Weiru as a new independent non-executive director, pending shareholder approval. Mr. Chen Weiru brings extensive experience in strategy formulation and corporate management, which is expected to enhance the board’s diversity and strategic capabilities.

More about Sinopharm Group Co

Sinopharm Group Co. Ltd. is a joint stock limited company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company is known for its focus on healthcare products and services, including the distribution of pharmaceuticals, medical devices, and other healthcare-related products.

YTD Price Performance: -14.18%

Average Trading Volume: 1,611

Technical Sentiment Signal: Buy

Current Market Cap: $7B

Learn more about 1099 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App